A new way to study the Complement System
Building on Svar’s expertise in cell-based complement assays, we introduce the iLite® C3a Assay Ready Cells, a new Mode-of-Action (MoA)-reflective assay for functional studies of C3a and its receptor C3aR. The iLite C3a Assay Ready Cells are optimized for potency testing in drug development, through receptor-specific readout of C3a activity, and for complement pathway research. This Research Use Only (RUO) cell line joins Svar’s unique portfolio of cell-based complement assays including the iLite® C5a Assay Ready Cells and the iLite® CD20 (+) Svar Luc Assay Ready Cells for complement-dependent cytotoxicity (CDC) studies.
As the focus on developing complement therapeutics grows, with the aim of delivering meaningful benefits to patients, researchers face significant challenges due to the inherent complexity of the complement system and the risk of unintended side effects. Highly specific, MoA-reflective cell-based assays have proven to be indispensable in successfully identifying and developing the most promising drug candidates that can deliver the desired therapeutic effect.